Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery

Study ID
NCT01182272

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

Trial Summary

RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sorafenib tosylate works in treating patients with liver cancer that can be removed by surgery.

More informations

Trial Starting Date

May 31,2010

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit